In biotech, observes Vir Biotechnology president and CEO George Scangos, it’s especially crucial to fully understand the market, and the means by which a new therapy will be purchased, prescribed and distributed. Many scientifically successful drugs, he points out, have been commercial failures—further demonstrating the importance of making sure the market is prepared to accept (and pay for) a new therapy.